Trial Profile
A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2020
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Pharmacodynamics; Proof of concept
- 03 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2012 New trial record